The article presents a retrospective analysis of 1000 medical records of patients suffering from CGP varying of different degree of severity, which were divided into two subgroups: BMI≥25 kg\m2 (572 patients), and BMI<25 kg\m2 (428 patients). A retrospective analysis has demenstrated a direct correlation of severity and frequency of the combination of CGP somatic disease (CVD, type 2 diabetes, diseases of the lungs and HKT ) in patients with a BMI≥25 kg/m2. The authors also presented a correlation analysis of the relationship of gravity CGP with biochemical status in 73 patients with CGP and BMI≥25 kg\m2, which conducted the study lipid - carbohydrate spectra of blood, activity state of systemic inflammation and oxidative status, the biomass of the bacterial flora of the mouth and intestines before and after treatment with the added attraction of probiotics (Simbiolakt comp.) and antioxidants (Ubiquinone comp.). The revealed high direct correlations bleeding index and severity of CGP (rIK - StHGP=0.89), BMI and bleeding index (rIMT - IR=0.79), atherogenic plasma (IA) and CGP (rIK -NA=0.72), pro-inflammatory status and BMI (rIMT - MDA=0.87) allowed the authors to conclude - CGP varying severity is independent risk factor for CVD in patients with a BMI≥25 kg\m2.
chronic periodontitis (CGP), atherogenic dyslipidemia, abdominal-visceral type of obesity, systemic inflammation, cardio - vascular diseases (CVD).
1. Biotsenoz kishechnika i serdechno-sosudistyy kontinuum / Arutyunov G.P., Kafarskaya L.I., Vlasen-ko V.K. [i dr.]. Serdechnaya nedostatochnost´. 2004. 5(5). S. 224-229;
2. Bazhanova O.E., Kamilov Kh.P., Zoyirov T.E. Optimizatsiya kompleksnogo lecheniya generalizovannogo parodontita. Materialy k IV mezhdunarodnoy konferentsii po klinicheskoy farmakologii i farmakotera-pii: aktual´nye voprosy, 2014. S. 29-30;
3. Golofeevskiy V.N. Vazhneyshie voprosy patomorfogeneza i lecheniya nealkogol´noy zhirovoy bo-lezni pecheni u bol´nykh sakharnym diabetom. Vrach. 2013. 7. S. 8-11;
4. Zvenigorodskaya L.A., Cherkasheva E.A., Nilova T.V. Nekotorye osobennosti lecheniya aterogennoy dislipidemii u bol´nykh s nealkogol´noy zhirovoy bolezn´yu pecheni. CONSILIUM MDICUM. 2011. T. 13, № 5. S. 110- 116;
5. Zorina O.A., Petrukhina N.B., Boriskina O.A., Berkutova I.S. Vzaimosvyaz´ kachestvennogo i koli-chestvennogo sostava biotsinozov rotovoy polosti i individual´nogo geneticheskogo profilya na fone vos-palitel´nykh zabolevaniy parodonta, 2012. S. 3-26;
6. Mikrobiologiya i immunologiya dlya stomatologov: [per. s angl.]. Pod red. R.Dzh. Lamonta, M.S. Lantts, R.A. Berne, D.Dzh. Leblanka; per. s angl. pod red. V.K. Leont´eva. M.: Prakticheskaya meditsina, 2010. 504 s.;
7. Papapanou P.N. Svyaz´ parodontita i ateroskleroza sosudov: aktual´nye dannye i znachimost´ dlya spetsialistov i obshchestva. Lechashchiy vrach. 2013. №7. S. 44-48;
8. Suvorov K.V. Parodontit i biotsinoz pishchevaritel´nogo trakta: etiopatogeneticheskie vzaimosvya-zi i klinicheskoe znachenie. Avtoreferat na soiskanie uchenoy stepeni kandidata meditsinskikh nauk. Tver´, 2013. S. 3-23;
9. Tkachenko E.I., Suvorova A.N. Disbioz kishechnika. Rukovodstvo po diagnostike i lecheniyu. SPb.: SpetsLit, 2006. S. 3-56;
10. Chikhacheva E.V., Teterina L.P. Narusheniya mikrobinoza kishechnika u patsientov s khronicheskimi zabolevaniyami pecheni. Vrach. 2013. 7. S. 34-39;
11. Shilov A.M., Zorina O.A. Petrukhina N.B. Disbioz kishechnika, parodontit i metabolicheski ass-tsiirovannye serdechno-sosudistye zabolevaniya. Farmateka. 2013. № 14. S. 85-91;
12. Shilov A.M., Mar´yanovskiy A.A., Petrukhina N.B., Zorina O.A. Epidemiologicheskie vzaimosvyazi parodontita, disbioza kishechnika. aterogennoy dislipidemii pri metabolicheskom sindrome. Lechebnoe delo. 2014. 3. S. 56-60;
13. Conrades V.M., Jorens P.G., De Clerck L.S. Selective intestinal decontamination in advanced chronic heart failure a pilot stady. Erop. J. Heart Fail. 2004. 6. R. 483-481;
14. Corraini P., Baelum V., Pannuti C.M., Romito G.A., Aquino D.R., Cortelli S.C., Cortelli J.R., Pustiglioni F.E. Subgingival microbial profiles as diagnostic markers of destructive periodontal diseases: A clinical epidemiol-ogy study. ActaOdontolScand. 2012. 3. R. 56;
15. D’Aiuto F., Orlandi M., Gunsolley J.C. Evidence that periodontal treatment improves biomarkers and CVD outcomes. J. Clin. Periodontal. 2013. 40 (in pess);
16. Gane E.J., Stedman C.A., Hyland R.H. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for he-patitis. N. Engl. J. Med., 2013. P. 34-44;
17. Lockhart P.B., Bolger A.F., Papapanou P.N. Periodontal disease and Atherosclerotic Vascular Disease: Does the Evidence Support an Independent Association?. A Scientific Statement from American Heart Associa-tion. Circulation. 2012. 125 (20). P. 2520-2544;
18. O’Beilly P,G., ClaffeyN.M. A History of. oral sepsis as cause of disease. Periodontal. 2000. 23. P. 13-18;
19. Sprading P., Rup L., Moorman A.C. Hepatitis B and C virus infection among 1,2 million persons with access to care factors associated with testing and infection prevalence. Clin. Infect. Dis. 2012. 55. 1047-1055.
20. Thiha K., Takeuchi Y., Umeda M. et al. Identificaionperiodontopatic bacteria in gingival tissue of Japa-nese periodontitis patients. Oral MicrobiolImmunol 2007. 22. №3. R. 201-207;
21. Tonetti M.S., Van Dyke T. Periodontitis and atherosclerotic cardiovascular disease. Consensus report of working group 1 of tht Joint European Federation of Periodontology and AmericanAcademy of Periodontology Workshop on Periodontitis and Systemic Diseas. J. Clin. Periodontal. 2013. 40 (in pess)
